A ramdomized trial evaluating the efficacy and safety of ENA 713 (Rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer disease for the ENA 713 B352 Study Group
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.